GENE ONLINE|News &
Opinion
Blog

.

Зеркало официального сайта всегда доступно для входа на Мостбет, даже при ограничениях. Скачать Mostbet – это шаг к удобству и азартным развлечениям.

Если вы ищете место для увлекательных ставок, обратите внимание на Joycasino, где лучшие предложения для игроков ждут вас.
2023-03-15| Trials & Approvals

Dermavant Eyes Second Vtama Indication with Topline Atopic Dermatitis Results

by Reed Slater
Share To

After gaining FDA approval in May last year to treat plaque psoriasis in adults, Dermavant recently announced positive Phase 3 trial results for its topical skin treatment, Vtama, evaluating the safety and efficacy of treating atopic dermatitis. If all goes well, Vtama could be a leading contender to Incyte’s newly-approved Opzelura in the atopic dermatitis arena. 

Competition in the Atopic Dermatitis Field

Atopic dermatitis, commonly called eczema, is one of the most common skin conditions in the world. Over 26 million people in the U.S. deal with the condition at any given time, prompting the constant need for more effective therapies to treat the ailment.

Dermavant designed Vtama as an aryl hydrocarbon receptor agonist and has already gained FDA approval to treat adults with plaque psoriasis. Now, the company is targeting its second indication for Vtama to compete with Incyte’s Opzelura. 

A key difference between Opzelura and Vtama is their mechanism of action. Incyte designed Opzelura as a Janus kinase (JAK) inhibitor, which prompted an FDA warning on its packaging. According to the FDA, JAK inhibitors can increase the risk of heart-related events, cancer, blood clots, and even death. 

Despite the concern, Opzelura, which the FDA approved in 2021 to treat atopic dermatitis, has done tremendously well on the market. The drug even went on to gain approval to treat vitiligo.

Dermavant is biting at Opzelura’s heels with Vtama, though, with some promising results from its Phase 3 ADORING 2 Trial. 

Related Article: Pfizer’s Fast-Acting Migraine Nasal Spray Takes Home US Approval

ADORING 2’s Optimistic Results

Seeing Vtama’s potential to treat atopic dermatitis across age ranges, Dermavant chose to include adult and pediatric patients in the ADORING 2 trial. Dermavant randomized the participants in a two-to-one ratio to receive Vtama or vehicle cream. 

The study accomplished its primary endpoint by clearing or almost clearing atopic dermatitis in 46.4% of participants after eight weeks. Additionally, Vtama cleared at least 75% of atopic dermatitis in 59.1% of the participants, accomplishing the secondary endpoint. 

Because Dermavant intends to market Vtama for use in children as young as two years old, the company highlighted the product’s safety, declaring that there are no serious safety or tolerability issues associated with the therapy. 

With some positive results bolstering Vtama’s position as a potential atopic dermatitis treatment, Incyte might have reason to worry about the future success of Opzelura. Until then, Dermavant will continue bringing in revenue from Vtama’s current indication, treating adults with plaque psoriasis. 

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Johnson & Johnson’s Bispecific Antibodies for Atopic Dermatitis and Talks of Biotech Partnerships at BIO 2024
2024-06-20
FDA OKs First Biologic for Children Under 5 With Moderate-to-Severe Atopic Dermatitis
2022-06-08
Kyowa Kirin, Amgen’s Atopic Dermatitis Drug Delivers Strong Results in Phase 2 Trial
2021-10-05
LATEST
Beyond Pouch Packaging: Hanmi Pharmaceutical Introduces a New Automated Vial Dispensing Solution in Canada and the United States
2025-02-13
NASA Says There’s a 1 in 43 Chance an Asteroid 2024 YR4 Could Hit Earth in 2032—Should We Worry?
2025-02-13
Sodium Channel Targeting: What the Latest FDA Non-Opioid Approval Reveals About the Next Big Thing in Pain Relief
2025-02-12
Novartis Reclaims Abelacimab in $925M Deal to Boost Cardiovascular Portfolio
2025-02-12
GLP-1 Weight Loss Drugs Might Cause Blindness
2025-02-11
South Korea’s Olix Strikes $660M Deal with Eli Lilly for Phase 1 MASH candidate
2025-02-11
22 USA States Sue Trump Administration for Slashing Critical Medical Research Funding
2025-02-11
EVENT
2025-02-19
Healthcare Conference Taipei 2025
Taipei, Taiwan
2025-03-04
MIXiii Health-Tech.IL
Jerusalem, Israel
2025-03-05
Medical Japan
Osaka, Japan
2025-03-17
BIO-Europe Spring 2025
Milan, Italy
2025-04-21
World Vaccine Congress 2025
Washington, U.S.A
Scroll to Top